Clinical trials: COVID-19 ARDS
SARS-CoV Infection, Acute Respiratory Distress Syndrome
Electrical Impedance Tomography: Collapse in Dependent Areas as a Predictor of Response to Prone Position Ventilation in COVID-19 Acute Respiratory Distress Syndrome
There are several clinical presentations of SARS-CoV-2 infection. Among the severe forms, pulmonary involvement with respiratory failure is common.
- Trial name
- COVIDEIT (NCT04603755)
- Testing
- Electrical Impedance tomography
- Where
- 2 sites in France
- Volunteers
- 50 people
- Sponsor
- Direction Centrale du Service de Santé des Armées
Acute Respiratory Distress Syndrome Secondary to Covid-19
Effect of Corticosteroid Treatment on Prognosis in ARDS Secondary to Covid-19
Study conducted on hospitalized patient in critical ill units in Nancy and Metz to evaluate if early corticosteroid treatment in first seven days after admission improve patients outcome in Acute Respiratory Distress Syndrome…
- Trial name
- CoCovSDRA (NCT04586114)
- Testing
- Corticosteroids and Derivatives
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Central Hospital, Nancy, France
Acute Respiratory Distress Syndrome, SARS-CoV-2
Evaluation of the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants With Acute Respiratory Distress Syndrome (ARDS) Associated With at Least Severe COVID-19
Evaluation of the safety, tolerability, and pharmacokinetics of PLN-74809 in participants with acute respiratory distress syndrome (ARDS) associated with at least severe COVID-19
- Trial name
- NCT04565249
- Testing
- PLN-74809
- Where
- 6 sites in United States
- Volunteers
- 6 people
- Sponsor
- Pliant Therapeutics, Inc.
Covid19, Novel Coronavirus Pneumonia
The Use of Exosomes for the Treatment of Acute Respiratory Distress Syndrome or Novel Coronavirus Pneumonia Caused by COVID-19
Novel coronavirus pneumonia (NCP) and acute respiratory distress syndrome (ARDS) are both associated with the prevailing upper respiratory tract infections caused by the RNA-containing SARS-CoV2 virus of the genius…
- Conditions
- Covid19, Novel Coronavirus Pneumonia, Acute Respiratory Distress Syndrome
- Trial name
- ARDOXSO (NCT04798716)
- Testing
- MSC-exosomes delivered intravenously every other day on an escalating dose: (2:4:8), MSC-exosomes delivered intravenously every other day on an escalating dose (8:4:8), MSC-exosomes delivered intravenously every other day (8:8:8)
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- AVEM HealthCare
COVID-19, SARS CoV 2 Virus
Passive Detection- SARS-CoV-2 (COVID-19) A&M Breathalyzer (PROTECT Kiosk) for Operational Medicine
The primary objective of this effort will be to optimize and operationalize innovative passive surveillance systems and in parallel, the effort will identify, evaluate, and transition groundbreaking new technologies in…
- Conditions
- COVID-19, SARS CoV 2 Virus, COVID-19 Pneumonia, COVID-19 Respiratory Infection
- Trial name
- COVID-19 (NCT06402318)
- Testing
- A&M Breathalyzer PROTECT Kiosk
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- The Geneva Foundation
COVID, ARDS, Human
Echocardiography in Patients With Covid-19
Prospective observational study of patients treated due to Covid-19 disease. Observation and analysis of echocardiographic studies performed in the intensive care setting.
- Trial name
- NCT04412460
- Where
- Germany
- Sponsor
- University Hospital Tuebingen
Pneumonia, Viral, Cytokine Storm
Ultra Low Doses of Therapy With Radiation Applicated to COVID-19
The host response against the coronavirus 2 (SARS-CoV-2) appears to be mediated by a 'cytoquine storm' developing a systemic inflammatory mechanism and an acute respiratory distress syndrome (ARDS), in the form of a bilateral…
- Trial name
- ULTRA-COVID (NCT04394182)
- Testing
- Ultra-Low-dose radiotherapy, ventilatory support with oxygen therapy, Lopinavir/ritonavir
- Where
- 2 sites in Spain
- Volunteers
- 15 people
- Sponsor
- Fundacion GenesisCare
Acute Respiratory Distress Syndrome, COVID19 Infection
Sedation With Sevoflurane Versus Propofol in Patients With Acute Respiratory Distress Syndrome Caused by COVID19 Infection
It is a multicenter, national, randomized 1:1 ratio, controlled, parallel, open study. Patients with severe ARDS-CoVid19 will be included in the trial within the first 24 hours.
- Trial name
- SEVO-COVID19 (NCT04359862)
- Testing
- Sevoflurane, Propofol
- Where
- 5 sites in Spain
- Volunteers
- 19 people
- Sponsor
- Fundación para la Investigación del Hospital Clínico de Valencia
COVID-19 Severe Pneumonia, Acute Lung Injury
Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia
This study evaluated the efficacy, safety, pharmacokinetics, and pharmacodynamics of ravulizumab administered in adult participants with coronavirus disease 2019 (COVID-19) severe pneumonia, acute lung injury, or acute…
- Conditions
- COVID-19 Severe Pneumonia, Acute Lung Injury, Acute Respiratory Distress Syndrome, Pneumonia, Viral
- Trial name
- NCT04369469
- Testing
- Ravulizumab, BSC
- Where
- 39 sites in United States, France and 3 more
- Volunteers
- 202 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Prone Position, Severe Acute Respiratory Syndrome Coronavirus 2
Evaluation of Sedation in COVID-19 ARDS
This study focuses on the evaluation of various factors repeatedly discussed in relation to the impaired sedation of intubated ventilated COVID-19 patients.
- Conditions
- Prone Position, Severe Acute Respiratory Syndrome Coronavirus 2, Hypnotics and Sedatives, Pulmonary Ventilation
- Trial name
- NCT04667936
- Testing
- Treatment group
- Where
- Germany
- Volunteers
- 114 people
- Sponsor
- Goethe University
ARDS, Human, Covid19
Regenerative Medicine for COVID-19 and Flu-Elicited ARDS Using Lomecel-B (RECOVER)
A Phase I, double- blinded, randomized, placebo- controlled study to test the safety of Lomecel-B in Adults suffering from mild to severe acute respiratory distress syndrome (ARDS) due to COVID-19 resultant from 2019-nCoV…
- Trial name
- RECOVER (NCT04629105)
- Testing
- Longeveron Mesenchymal Stem Cells (LMSCs)
- Where
- 3 sites in United States
- Volunteers
- 70 people
- Sponsor
- Longeveron Inc.
ARDS, Human, Mechanical Ventilation Complication
Awake Prone Positioning to Reduce Invasive VEntilation in COVID-19 Induced Acute Respiratory failurE
Prone positioning (PP) is an effective first-line intervention to treat moderate-severe acute respiratory distress syndrome (ARDS) patients receiving invasive mechanical ventilation, as it improves gas exchanges and lowers…
- Conditions
- ARDS, Human, Mechanical Ventilation Complication, COVID19
- Trial name
- APPROVE-CARE (NCT04347941)
- Testing
- Prone Positioning, Standard of care.
- Where
- Ireland
- Volunteers
- 24 people
- Sponsor
- University College Hospital Galway
COVID, Severe Acute Respiratory Syndrome
LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19)
To evaluate the proportion of subjects alive and free of respiratory failure (e.g. need for non-invasive or invasive mechanical ventilation, high flow oxygen, or ECMO) and free of the need for continued renal replacement therapy…
- Conditions
- COVID, Severe Acute Respiratory Syndrome, Sars-CoV2, Acute Kidney Injury
- Trial name
- NCT04402957
- Testing
- LSALT peptide
- Where
- 7 sites in United States, Canada and 1 more
- Volunteers
- 61 people
- Sponsor
- Arch Biopartners Inc.
COVID-19 Acute Respiratory Distress Syndrome, Immunosuppression
Booster Dose of COVID-19 Vaccine for Kidney Transplant Recipients Without Adequate Humoral Response
Introduction: Inadequate antibody response to mRNA SARS-CoV-2 vaccination has been described among kidney transplant recipients.
- Trial name
- WHO (NCT04961229)
- Testing
- The Pfizer mRNA-based BNT162b2 vaccine
- Volunteers
- 504 people
- Sponsor
- dafna yahav
ARDS, Human
AllogeneiC Expanded Human MSC Therapy in Patients Recovering From COVID-19 Acute Respiratory Distress Trial
Allogeneic culture-expanded bone marrow-derived human mesenchymal stem cells (MSC) are the subject of the current study as they are supported by preclinical and clinical data for potential to provide a safe and effective…
- Trial name
- ACE_CARD (NCT05491681)
- Testing
- intravenous delivery of allogeneic bone marrow-derived MSCs
- Sponsor
- BioCardia, Inc.
Respiratory Distress Syndrome, Adult, COVID-19
Coronavirus Studied by Metagenomics in ARDS COVID-19 Patients
Pandemic SARS-CoV-2 (COVID-19) respiratory infection is responsible for more than 4,000 deaths, mainly (67%) secondary to acute respiratory distress syndromes (ARDS).
- Trial name
- COMETS (NCT04516486)
- Testing
- retrospective metagenomics on clinical samples collected during hospitalization
- Where
- France
- Volunteers
- 180 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Respiratory Failure, ARDS
Plasma Adsorption in Patients With Confirmed COVID-19
To characterize the ability of the D2000 Cartridge in combination with the Optia SPD Protocol to reduce the morbidity and mortality associated with SARS-CoV-2 infection in patients admitted to the ICU.
- Trial name
- NCT04358003
- Testing
- Marker Therapeutics D2000 Cartridge (D2000) for use with the Spectra Optia® Apheresis System (Optia SPD Protocol)
- Where
- 7 sites in United States
- Volunteers
- 107 people
- Sponsor
- Marker Therapeutics AG
Severe Acute Respiratory Syndrome Coronavirus 2
Ruxolitinib for the Treatment of Acute Respiratory Distress Syndrome in Patients With COVID-19 Infection
It is an observational, cohort, retrospective, monocentric, non-profit study. The primary objective is to evaluate the efficacy and safety of ruxolitinib in acute respiratory distress syndrome in patients with SARS-CoV-2 COVID-19…
- Trial name
- RESPIRE (NCT04361903)
- Testing
- Ruxolitinib Oral Tablet
- Volunteers
- 13 people
- Sponsor
- Azienda USL Toscana Nord Ovest
Covid19 Pneumonia
Prevention of COVID-19 Infection to Severe Pneumonia or ARDS
A trial of EC-18 in patients with mild/moderate pneumonia due to COVID-19
- Trial name
- NCT04569227
- Testing
- EC-18
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Enzychem Lifesciences Corporation
ARDS Due to Disease Caused by SARS Co-V-2
Clinical Effects of Sivelestat Sodium on Improving ARDS in Patients With COVID-19
The goal of this retrospective multicentre cohort study is to examine the association between receipt of sivelestat and improvement in oxygenation among patients with acute respiratory distress syndrome (ARDS) induced by…
- Trial name
- NCT06218862
- Testing
- Sivelestat sodium, Control
- Where
- China
- Volunteers
- 387 people
- Sponsor
- The First Hospital of Jilin University